https://www.selleckchem.com/pr....oducts/elacestrant.h
7% and a specificity of 81.6%. In 62 treatment-naïve patients without metastases, multivariate analysis identified the presence of ctDNA as an independent prognostic factor (hazard ratio 6.311, P=.001). Circulating tumor DNA can help predict the presence of occult metastases in pancreatic cancer patients with radiographically non-metastatic disease. Circulating tumor DNA can help predict the presence of occult metastases in pancreatic cancer patients with radiographically non-metastatic disease. There are limitations in obtaining su
Curtir
Comentario
Compartilhar
